|
Accession number;99A1042711
|
| Title;PET application in Psychiatry and Psychopharmacology. |
| Author;
SUHARA TETSUYA
(National Inst. of Radiological Sciences)
|
Journal Title;NIRS-M (Natl Inst Radiol Sci)
|
Journal Code:Z0881A
|
ISSN:
|
|
VOL.;NO.132;PAGE.14-22(1999)
|
| Figure&Table&Reference;FIG.4, REF.37 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;In the last few decades diagnostic and research tools in the medical field have made great advances, yet psychiatry has lacked sufficiently sensitive tools to measure the aberration of brain functions. Recently however, the development of Positron emission topmgraphy (PET) techniques has made it possible to measure changes in neurochemical components in mental disorders and the effect of psychoactive drugs in living human brain. Most of the advancement in the psychiatric field has came from the development psychoactive drugs. Brain research involving identification of neurotransmission is largely based on compounds developed in psychopharmacology. Some of these compounds have been radiolabelled and used as radioligands for quantitative examination of neuroreceptors and other aspects of neurotransmission. Using PET, radioligand binding can now be examined in the human brain in vivo. PET techniques also allow examination of an unlabelled drug by examination of its interaction with a radioligand. So one potential of PET in psychiatry is to investigate the mechanism of psychoactive drugs. Antidepressants modulate serotonin transmission by inhibiting serotonin reuptake from the synaptic cleft. High affinity [3H]imipramine binding sites in mammalian brain have been labeled to investigate serotonin transporters in living human brain by PET. Cyanoimipramine which is described as a potent serotonin reuptake inhibitor, was labeled with 11C. In a PET experiment with 6 healthy human subjects, a high accumulation of [11C]cyanoimipramine was found in the thalamus and striatum and lowest accumulation was observed in the cerebellum, a region relatively void of serotonin transporters. The thalamus to cerebellum ratio was about 2 at 90 min after the injection of the tracer. Recently, [11C]McN5652-X has been introduced as a better tracer for seratonin transporter imaging.... (author abst.) |
|
|
|
Related Articles;
|
